Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) generates news that spans drug delivery technology, clinical applications, strategic collaborations and corporate finance. As a biopharmaceutical company focused on subcutaneous administration of biologics, Halozyme’s announcements often highlight how its ENHANZE and Hypercon platforms are being integrated into partner therapies and new indications.
News items frequently cover collaboration and license agreements with global pharmaceutical and biotechnology companies. Examples include agreements with Takeda to use ENHANZE with vedolizumab and with Merus to develop a subcutaneous formulation of petosemtamab. These stories typically describe upfront payments, potential milestones and royalty structures, as well as the therapeutic areas targeted by ENHANZE-enabled products.
Another major category of HALO news involves regulatory milestones achieved by partner products that incorporate Halozyme technologies. Recent press releases describe U.S. Food and Drug Administration approvals for DARZALEX Faspro and RYBREVANT FASPRO, both co-formulated with ENHANZE, in multiple myeloma and EGFR-mutated non-small cell lung cancer. Such updates provide insight into how Halozyme’s platforms translate into commercial products and expanded indications.
Halozyme also issues updates on intellectual property and legal matters, including patent enforcement actions related to its MDASE portfolio and court decisions affecting subcutaneous formulations of other companies’ drugs. In addition, investors can follow corporate developments such as acquisitions, including the purchase of Elektrofi and its Hypercon technology, board appointments, executive transitions and participation in healthcare conferences.
For investors and industry observers, the HALO news feed offers a way to track the evolution of Halozyme’s partnership base, the progress of ENHANZE- and Hypercon-enabled products, and key events that may influence the company’s royalty outlook and strategic direction.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced plans to release its first-quarter 2023 financial and operating results on May 9, 2023, after the trading day concludes. A conference call will follow at 4:30 p.m. ET to discuss the results, accessible via pre-registration.
The call will also be available as a live webcast on the company's website. Halozyme is focused on enhancing patient experiences through its innovative ENHANZE® technology, which improves the delivery of injected medications. As of now, it has impacted over 700,000 patients globally.
Halozyme partners with major pharmaceutical firms like Roche and Pfizer, and it has a range of commercial products, including XYOSTED®, TLANDO®, and NOCDURNA®.
Halozyme Therapeutics (NASDAQ: HALO) announced that the recent decision by the European Patent Office regarding a co-formulation patent for DARZALEX FASPRO® will not affect its U.S. and European royalty revenues through at least 2030. The company reaffirms its 2023 revenue guidance, estimating total revenue between $815 million and $845 million, and royalty revenue between $445 million and $455 million. Despite the revocation of the European Patent EP3370770B1, Halozyme expects to maintain royalty payments from Janssen. A written decision is forthcoming, and an appeal could suspend the decision temporarily.
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
